Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Nasopharyngeal Carcinoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Respiratory Tract Diseases 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

tislelizumab 2sugemalimab 2pegaspargase 2IMC-001 2Gemcitabine 2tipifarnib 1relatlimab 1ontuxizumab 1gemcitabine-oxaliplatin regimen 1camrelizumab 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Sensitivity and Specificity 1Oxaliplatin 1Nivolumab 1Mannose-Binding Lectin 1Ice 1Folic Acid 1Commerce 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Extranodal NK-T-Cell × camrelizumab × Clear all
NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
97 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡